CA
BIO icon

Calton & Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Calton & Associates’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-338
Closed -$255K – 358
2021
Q4 		$255K Sell
338
-7
-2% -$5.24K 0.07% 299
2021
Q3 		$257K Sell
345
-2
-0.6% -$1.5K 0.06% 321
2021
Q2 		$224K Sell
347
-12
-3% -$7.3K 0.04% 359
2021
Q1 		$205K Sell
359
-1
-0.3% -$592 0.04% 374
2020
Q4 		$210K Buy
+360
New +$205K 0.04% 359

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Calton & Associates's BIO Position: Q1 2022 in Review

Calton & Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 338 shares — an estimated $255K sold.

Calton & Associates first reported a position in BIO in Q4 2020 and held it in 5 quarters. The position peaked at $257K in Q3 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • Calton & Associates reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
  • Calton & Associates sold 338 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $255K.
  • Calton & Associates first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 5 quarters.
  • Calton & Associates's Bio-Rad Laboratories Class A position peaked at $257K in Q3 2021.
  • 514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Calton & Associates's 13F filing for Q1 2022, filed 12 Apr 2022.